Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/36183
Title: Combinational Therapy of Cardiac Atrial Appendage Stem Cells and Pyridoxamine: The Road to Cardiac Repair?
Authors: EVENS, Lize 
BELIEN, Hanne 
D'HAESE, Sarah 
HAESEN, Sibren 
VERBOVEN, Maxim 
RUMMENS, Jean-Luc 
BRONCKAERS, Annelies 
HENDRIKX, Marc 
DELUYKER, Dorien 
BITO, Virginie 
Issue Date: 2021
Publisher: MDPI
Source: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCE, 22 (17) , (Art N° 9266)
Abstract: Myocardial infarction (MI) occurs when the coronary blood supply is interrupted. As a consequence, cardiomyocytes are irreversibly damaged and lost. Unfortunately, current therapies for MI are unable to prevent progression towards heart failure. As the renewal rate of cardiomyocytes is minimal, the optimal treatment should achieve effective cardiac regeneration, possibly with stem cells transplantation. In that context, our research group identified the cardiac atrial appendage stem cells (CASCs) as a new cellular therapy. However, CASCs are transplanted into a hostile environment, with elevated levels of advanced glycation end products (AGEs), which may affect their regenerative potential. In this study, we hypothesize that pyridoxamine (PM), a vitamin B6 derivative, could further enhance the regenerative capacities of CASCs transplanted after MI by reducing AGEs' formation. Methods and Results: MI was induced in rats by ligation of the left anterior descending artery. Animals were assigned to either no therapy (MI), CASCs transplantation (MI + CASCs), or CASCs transplantation supplemented with PM treatment (MI + CASCs + PM). Four weeks post-surgery, global cardiac function and infarct size were improved upon CASCs transplantation. Interstitial collagen deposition, evaluated on cryosections, was decreased in the MI animals transplanted with CASCs. Contractile properties of resident left ventricular cardiomyocytes were assessed by unloaded cell shortening. CASCs transplantation prevented cardiomyocyte shortening deterioration. Even if PM significantly reduced cardiac levels of AGEs, cardiac outcome was not further improved. Conclusion: Limiting AGEs' formation with PM during an ischemic injury in vivo did not further enhance the improved cardiac phenotype obtained with CASCs transplantation. Whether AGEs play an important deleterious role in the setting of stem cell therapy after MI warrants further examination.
Notes: Bito, V (corresponding author), UHasselt Hasselt Univ, BIOMED Biomed Res Inst, Agoralaan, B-3590 Diepenbeek, Belgium.
lize.evens@uhasselt.be; hanne.belien@uhasselt.be;
sarah.dhaese@uhasselt.be; sibren.haesen@uhasselt.be;
maxim.verboven90@gmail.com; jeanluc.rummens@uhasselt.be;
annelies.bronckaers@uhasselt.be; marc.hendrikx@uhasselt.be;
dorien.deluyker@uhasselt.be; virginie.bito@uhasselt.be
Keywords: stem cells; CASCs; advanced glycation end products; glycated proteins;;myocardial infarction; transplantation; remodeling; cardiomyocytes;;aldehyde dehydrogenase
Document URI: http://hdl.handle.net/1942/36183
ISSN: 1661-6596
e-ISSN: 1422-0067
DOI: 10.3390/ijms22179266
ISI #: WOS:000694332900001
Rights: Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Category: A1
Type: Journal Contribution
Validations: ecoom 2022
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
ijms-22-09266.pdfPublished version2.19 MBAdobe PDFView/Open
Show full item record

WEB OF SCIENCETM
Citations

3
checked on Apr 15, 2024

Page view(s)

38
checked on Jun 14, 2022

Download(s)

14
checked on Jun 14, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.